title: Tissue factor and cancer stem cells: is there a linkage?
abstract: A common feature in the progression of multiple human malignancies is the protracted deregulation of the coagulation system, often referred to as cancer coagulopathy. Indeed, cancer cells and their vascular stroma often exhibit procoagulant properties, of which deregulation of tissue factor (TF) expression is a notable, although not the sole example. These changes can be traced to oncogenic influences affecting epidermal growth factor receptor (EGFR), EGFRvIII, K-ras, p53, PTEN, and probably many other proto-oncogenes and tumor suppressors in tumor parenchyma. Cancer stem cells (CSCs)/tumor initiating cells (TICs) are thought to represent the primary target and the main cellular effector through which oncogenic mutations exert their tumor-inducing effects. In so doing, CSCs/TICs depend on interactions with the tumor vasculature, which forms supportive niches for their clonal growth. We postulate that TF contributes to these interactions (directly or indirectly) through procoagulant and signaling effects, the latter executed in concert with juxtaposed protease activated receptors (mainly PAR-1 and PAR-2). TF/PAR system acts as a "blood sensing" mechanism, whereby cancer cells, including CSCs/TICs, may respond to plasma proteases (Factors VIIa, Xa, and IIa) and their related microenvironmental changes (fibrin deposition, activation of platelets). A growing body of still largely circumstantial evidence suggests that these events may contribute to the CSC/TIC niche, which could influence tumor initiation, metastasis, recurrence, and therapeutic intractability. Indeed, certain types of cancer cells harboring markers of CSCs (CD133) exhibit elevated TF expression and depend on this receptor to efficiently initiate tumor growth. We propose that both tumor cell-associated and host-related TF could influence the properties of CSCs, and that agents targeting the TF/PAR system may represent a hitherto unappreciated therapeutic opportunity to control cancer progression by influencing the CSC/TIC compartment.
authors.affiliation: Montreal Children's Hospital, McGill University, QC, Canada.
authors.forename: Chloe
authors.initials: C
authors.lastname: Milsom
authors.forename: Nathalie
authors.initials: N
authors.lastname: Magnus
authors.forename: Brian
authors.initials: B
authors.lastname: Meehan
authors.forename: Khalid
authors.initials: K
authors.lastname: Al-Nedawi
authors.forename: Delphine
authors.initials: D
authors.lastname: Garnier
authors.forename: Janusz
authors.initials: J
authors.lastname: Rak
mesh_terms: D001777:Blood Coagulation; D002471:Cell Transformation, Neoplastic; D016147:Genes, Tumor Suppressor; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000097:blood / Q000098:blood supply / Q000209:etiology / Q000503:physiopathology; D014411:Neoplastic Stem Cells / Q000502:physiology*; D009389:Neovascularization, Pathologic; D009857:Oncogenes; D044462:Receptors, Proteinase-Activated / Q000502:physiology; D015398:Signal Transduction; D013925:Thromboplastin / Q000502:physiology*
chemical_list: D044462:Receptors, Proteinase-Activated; D013925:Thromboplastin